Читать книгу Interventional Cardiology - Группа авторов - Страница 307

1 1 DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non‐Q‐wave myocardial infarction. The New England Journal of Medicine 1986; 315:417–23.

2 2 Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC). Eur Heart Jnl. 2016; 37:267–315.

3 3 Chew DP, Lambrakis K, Blyth A, et al. A Randomized Trial of a 1‐Hour Troponin T Protocol in Suspected Acute Coronary Syndromes: The Rapid Assessment of Possible Acute Coronary Syndrome in the Emergency Department With High‐Sensitivity Troponin T Study (RAPID‐TnT). Circulation 2019; 140:1543–56.

4 4 Frick, M. High‐sensitivity cardiac troponin at presentation to rule out myocardial infarction (HiSTORIC): a stepped‐wedge cluster‐randomised controlled trial. ESC Paris, France.2019.

5 5 Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ open 2014; 4:e004425.

6 6 Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non‐ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835–42.

7 7 Amsterdam EA, Wenger NK. The 2014 American College of Cardiology ACC/American Heart Association guideline for the management of patients with non‐ST‐elevation acute coronary syndromes: ten contemporary recommendations to aid clinicians in optimizing patient outcomes. Clinical Cardiology 2015; 38:121–3.

8 8 Leonardi S, Armstrong PW, Schulte PJ, et al. Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart Jnl. 2013; 34:894‐902d.

9 9 O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non‐ST‐segment elevation myocardial infarction: a meta‐analysis. JAMA 2008; 300:71–80.

10 10 Fox KA, Clayton TC, Damman P, et al. Long‐term outcome of a routine versus selective invasive strategy in patients with non‐ST‐segment elevation acute coronary syndrome a meta‐analysis of individual patient data. J Am Coll Cardiol 2010; 55:2435–45.

11 11 Tegn N, Abdelnoor M, Aaberge L, et al. Invasive versus conservative strategy in patients aged 80 years or older with non‐ST‐elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open‐label randomised controlled trial. The Lancet (London, England) 2016; 387:1057–65.

12 12 Wallentin L, Lindhagen L, Arnstrom E, et al. Early invasive versus non‐invasive treatment in patients with non‐ST‐elevation acute coronary syndrome (FRISC‐II): 15 year follow‐up of a prospective, randomised, multicentre study. The Lancet (London, England) 2016; 388:1903–11.

13 13 Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non‐ST‐Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 64:e139–e228.

14 14 Neumann FJ, Sousa‐Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40:87–165.

15 15 Lopes RD, Leonardi S, Neely B, et al. Spontaneous MI After Non‐ST‐Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. J Am Coll Cardiol. 2016; 67:1289–97.

16 16 Jobs A, Mehta SR, Montalescot G, et al. Optimal timing of an invasive strategy in patients with non‐ST‐elevation acute coronary syndrome: a meta‐analysis of randomised trials. The Lancet (London, England) 2017; 390:737–46.

17 17 Kofoed KF, Kelbaek H, Hansen PR, et al. Early Versus Standard Care Invasive Examination and Treatment of Patients With Non‐ST‐Segment Elevation Acute Coronary Syndrome. Circulation 2018; 138:2741–50.

18 18 Valgimigli M, Gagnor A, Calabro P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. The Lancet 2015; 385:2465–76.

19 19 Holmes DR, Jr., Rich JB, Zoghbi WA, Mack MJ. The heart team of cardiovascular care. J Am Coll Cardiol. 2013; 61:903–7.

20 20 Ben‐Gal Y, Moses JW, Mehran R, et al. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC Cardiovascular interventions 2010; 3:1059–67.

21 21 Freitas P, Madeira M, Raposo L, et al. Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Non‐ST‐Elevation Myocardial Infarction and Left Main or Multivessel Coronary Disease. The American Journal of Cardiology 2019; 123:717–24.

22 22 Garcia S, Sandoval Y, Roukoz H, et al. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta‐analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J Am Coll Cardiol 2013; 62:1421–31.

23 23 Rathod KS, Koganti S, Jain AK, et al. Complete Versus Culprit‐Only Lesion Intervention in Patients With Acute Coronary Syndromes. J Am Coll Cardiol 2018; 72:1989–99.

24 24 Sardella G, Lucisano L, Garbo R, et al. Single‐Staged Compared With Multi‐Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial. J Am Coll Cardiol. 2016; 67:264–72.

25 25 Kubo T, Imanishi T, Takarada S, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol. 2007; 50:933–9.

26 26 Iannaccone M, D'Ascenzo F, Frangieh AH, et al. Impact of an optical coherence tomography guided approach in acute coronary syndromes: A propensity matched analysis from the international FORMIDABLE‐CARDIOGROUP IV and USZ registry. Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography and Interventions 2017; 90:E46‐e52.

27 27 Meneveau N, Souteyrand G, Motreff P, et al. Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non‐ST‐Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting). Circulation 2016; 134:906–17.

28 28 Stub D, Smith K, Bernard S, et al. Air Versus Oxygen in ST‐Segment‐Elevation Myocardial Infarction. Circulation 2015; 131:2143–50.

29 29 Hofmann R, James SK, Jernberg T, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. N Engl J Med.2017; 377:1240–9.

30 30 Borzak S, Cannon CP, Kraft PL, et al. Effects of prior aspirin and anti‐ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. J Am Coll Cardiol. 1998; 81:678–81.

31 31 Chatterjee S, Chaudhuri D, Vedanthan R, et al. Early intravenous beta‐blockers in patients with acute coronary syndrome‐‐a meta‐analysis of randomized trials. International Journal of Cardiology 2013; 168:915–21.

32 32 Yasue H, Takizawa A, Nagao M, et al. Long‐term prognosis for patients with variant angina and influential factors. Circulation 1988; 78:1–9.

33 33 Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. JAMA 2013; 310:189–98.

34 34 Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med.2001; 345:494–502.

35 35 Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010; 363:930–42.

36 36 Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303:754–62.

37 37 Claassens DMF, Vos GJA, Bergmeijer TO, et al. A Genotype‐Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med. 2019; 381:1621–31.

38 38 Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON‐TIMI 38 trial: a subanalysis of a randomised trial. The Lancet (London, England) 2008; 371:1353–63.

39 39 Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2007; 357:2001–15.

40 40 Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non‐ST‐segment elevation acute coronary syndromes. New Engl J Med. 2013; 369:999–1010.

41 41 Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. New Engl J Med. 2012; 367:1297–309.

42 42 Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361:1045–57.

43 43 Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124:544–54.

44 44 Schupke S, Neumann FJ, Menichelli M, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381:1524–34.

45 45 Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE‐DAPT) score: a pooled analysis of individual‐patient datasets from clinical trials. The Lancet 2017; 389:1025–34.

46 46 Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio‐Thoracic Surgery (EACTS). Eur Heart J. 2018; 39:213–60.

47 47 Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68:1082–115.

48 48 Watanabe H, Domei T, Morimoto T, et al. Effect of 1‐Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12‐Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT‐2 Randomized Clinical Trial. JAMA 2019; 321:2414–27.

49 49 Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART‐CHOICE Randomized Clinical Trial. JAMA 2019; 321:2428–37.

50 50 Tomaniak M, Chichareon P, Onuma Y, et al. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. JAMA cardiology 2019.

51 51 Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High‐Risk Patients after PCI. N Engl J Med. 2019; 381:2032–42.

52 52 Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019; 40:2632–53.

53 53 Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient‐level data. The Lancet (London, England) 2013; 382:1981–92.

54 54 Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361:2318–29.

55 55 Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta‐analysis of all major randomised clinical trials. The Lancet (London, England) 2002; 359:189–98.

56 56 Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high‐risk patients with non‐ST‐segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45–54.

57 57 Silvain J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta‐analysis. BMJ (Clinical researched) 2012; 344:e553.

58 58 Steg PG, Jolly SS, Mehta SR, et al. Low‐dose vs standard‐dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS‐8 randomized trial. JAMA 2010; 304:1339–49.

59 59 Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. The Lancet (London, England) 2007; 369:907–19.

60 60 Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355:2203–16.

61 61 Erlinge D, Omerovic E, Frobert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017; 377:1132–42.

62 62 Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015; 373:997–1009.